Exchange: OTC·Updated 02:27 PM EDT

EFTR eFFECTOR Therapeutics Inc

$0.0003
$0.0005
(62.50%)
Today
Reported EarningsMay 9
Mkt Cap$1,411.00
Vol1.00

About EFTR

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Foxborough, MA.
50

Neutral Sentiment

How do you feel about EFTR?

Advertisement|Remove ads.